Article
Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update.
Cancer investigation - 1 Jun 2012
Ayoola Ayodele, Barochia Amit, Belani Kiran, Belani Chandra P
Abstract excerpt
Epidermal growth factor receptor (EGFR) is a critical target in the treatment of nonsmall cell lung cancer (NSCLC). The mutations involving EGFR are more prevalent in patients of Asian ancestry, women, never smokers, and those with adenocarcinoma histology. Primary mechanism of resistance to EGFR-TKIs includes in frame insertion mutation in exon 20, de novo T790M mutation also on exon 20, activating mutations in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.